Abstract
Whether inhibition of thymidylate synthase is lethal to a population of tumor cells depends upon three factors: 1) the dependence of the cells upon de novo synthesis of thymidine nucleotides; 2) the length of time enzyme is inhibited and the requirement for thymidine nucleotides during this period; and 3) the biochemical responses of the cells to the initial inhibition of enzyme, many of which interfere with maintenence of thymidylate synthase in an inhibited state. Following inhibition of thymidylate synthase, deoxyuridylate accumulates, as does the cellular content of thymidylate synthase. In addition, the initially formed enzyme-inhibitor complexes dissociate. These biochemical sequelae alter the effectiveness of the blockade of thymidylate synthase in a time-dependent, continuously-changing manner. Whether cell kill occurs depends on whether the dynamic balance of these factors allows a sufficiently low enzymatic activity to be maintained for a long enough period of time.
An analysis of this interaction of factors leads us to the conclusions that efficient tumor cell kill with fluoropyrimidines is best attained by combination with reduced folate cofactors and inhibitors of deoxypyrimidine biosynthesis. Each of these agents modifies the response of tumor cells with the result that the fluorodeoxyuridylate-induced inhibition of thymidylate synthase is maintained. This analysis also suggests that folate analogs inhibitory to thymidylate synthase are more compatible than pyrimidine analogs with inhibition of thymidylate synthase as an approach to cancer chemotherapy.
This work was supported in part by USPHS grant CA-36054 from the National Cancer Institute. RGM is a Scholar of the Leukemia Society of America.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Heidelberger, C., Danenberg, P.V., and Moran, R.G. (1983) Adv. Enzymol. 54, 57–119.
Keyomarsi, K. and Moran, R.G. (1988) J. Biol. Chem., submitted.
Myers, C.E., Young, R.C., and Chabner, B.A. (1975) J. Clin. Invest. 56, 1231–1238
Moran, R.G., Spears, C.P., and Heidelberger, C. (1979) Proc. Natl. Acad. Sci., USA. 76, 1456–1460.
Jackson, R.C. (1978) J. Biol. Chem. 253: 7440–7446.
Lorenson, M.Y., Maley, G.F., and Maley, F. (1967) J.Biol.Chem. 242: 3332–3344.
Moore, E.C. and Huribert, R.B. (1966) J.Biol. Chem. 241: 4802–4809.
Spears, C.P., Gustaysson, B.G., Mitchell, M.S., Spicer, D., Berne, M., Bernstein, L., and Danenberg, P.V. (1984) Cancer Res. 44: 4144–4150.
Jackman, A.L., Alison, D.A., Calvert, A.H., and Harrup, K.R. (1986) Cancer Res. 46: 2810–2815.
Lockshin, A., Moran, R.G., and Danenberg, P.V. (1979) Proc. Natl Acad. Sci., USA. 76, 750–754.
Spears, C.P., Shahinian, A.H., Moran, R.G., and Heidelberger, C. (1982) Cancer Res. 42, 450–456.
Keyomarsi, K. and Moran, R.G. (1986) Cancer Res. 46, 5229–5235.
Goldman, I.D., (1974) Mol. Pharmacol. 10, 257–274
White, J.C., and Goldman, I.D. (1976) Mol. Pharmacol. 12, 711–719
Santi, D.V., McHenry, C.S., and Perriard, E.R. (1974) Biochemistry 13: 467–470
Ullman, B., Melinda, L., Martin, D.W., and Santi, D.V (1978) Proc. Natl. Acad. Sci. U.S.A. 75, 980–983
Evans, R.M., Laskin, J.D., and Hakala, M.T. (1981) Cancer Res. 41, 3288–3295
Evans, R.M., Laskin, J.D., and Hakala, M.T. (1980) Cancer Res. 40, 4113–4122
Cohen, L.S., and Studzinski, G.P. (1967) J. Cell Physiol. 69, 331–340
Rueckert, R.R., and Mueller, G.C. (1960) Cancer Res. 20, 1584–1591
Maalge, O., and Hanawalt, P.C. (1961) J. Mol. Biol. 3, 144–155
Lockshin, A., and Danenberg, P. V. (1981) Biochem. Pharmacol. 30, 247–257
Galivan., J. H., Maley, G.F., and Maley, F. (1976) Biochemistry 15: 356–362.
Moran, R.G., Danenberg, P.V., and Heidelberger, C. (1982) Biochem.Ph arm aco1. 31, 2929–2935.
Unpublished observations.
Klubes, P., Cerna, I., and Meldon, M.A. (1982) Cancer Chemother. Pharmacol. 8: 17–21.
Martin, D.S., Stolfi, R.L., Sawyer, R.C., Speigelman, S., and Young, C.W. (1983) Cancer Res. 43, 4653–4661
Jones, T.R., Calvert, A.H., Jackman,A.L., Brown, S.J., Jones, M., and Hanap, K.R. (1981) Eur. J. Cancer 17: 11–19.
Jackson, R.C., Jackman, A.L., and Calvert, A.H. (1983) Biochem. Pharmacol. 32: 3783–3790.
Pogolotti, A. L., Danenberg, P.V., Santi, D.V. (1986) J. Med. Chem. 29: 478–482.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Plenum Press, New York
About this chapter
Cite this chapter
Moran, R.G., Keyomarsi, K., Patel, R. (1988). Tumor Cell Responses to Inhibition of Thymidylate Synthase. In: Rustum, Y., McGuire, J.J. (eds) The Expanding Role of Folates and Fluoropyrimidines in Cancer Chemotherapy. Advances in Experimental Medicine and Biology, vol 244. Springer, New York, NY. https://doi.org/10.1007/978-1-4684-5607-3_7
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5607-3_7
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4684-5609-7
Online ISBN: 978-1-4684-5607-3
eBook Packages: Springer Book Archive